Table 1 Demographic data and characteristics of the main study cohort at the 12-month collection round

From: Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk

 

Total (N = 1325)a

Infection-naive (N = 955)b

Infected before Omicron (N = 207)c

Infected with Omicron (N = 163)d

P-value

Sex

    Female

1145 (86.4%)

833 (87.2%)

180 (87.0%)

132 (81.0%)

0.0961e

    Male

180 (13.6%)

122 (12.8%)

27 (13.0%)

31 (19.0%)

 

Age (years)

    Median (IQR)

52 (41–59)

54 (43–61)

47 (36–57)

46 (39–55)

<0.0001e

     <40

316 (23.8%)

193 (20.2%)

70 (33.8%)

53 (32.5%)

<0.0001f

    >40–60

718 (54.2%)

518 (54.2%)

107 (51.7%)

93 (57.1%)

 

    >60

291 (22.0%)

244 (25.5%)

30 (14.5%)

17 (10.4%)

 

BMI

    Median (IQR)

24 (22–27)g

24 (22–27)h

24 (22–27)i

24 (22–26)j

0.3646e

    Underweight

17 (1.4%)

10 (1.2%)

6 (3.1%)

1 (0.8%)

0.0626f

    Normal

681 (57.9%)

480 (56.3%)

115 (60.2%)

86 (64.7%)

    Overweight

305 (25.9%)

227 (26.6%)

43 (22.5%)

35 (26.3%)

    Obese

174 (14.8%)

136 (15.9%)

27 (14.1%)

11 (8.3%)

Infection status

    Infected before Omicron

129 (9.7%)

N.A.

129 (62.3%)

N.A.

N.A.

     Ancestral variantk

54 (20.2%)

N.A.

54 (41.9%)

N.A.

     Alpha variant

19 (7.1%)

N.A.

19 (14.7%)

N.A.

     Delta variant

56 (21.0%)

N.A.

56 (43.4%)

N.A.

    Infected before Omicron and reinfected

78 (5.9%)

N.A.

78 (37.7%)

N.A.

     Ancestral variantk

46 (28.5%)

N.A.

46 (59.0%)

N.A.

     Alpha variant

19 (11.8%)

N.A.

19 (24.4%)

N.A.

     Delta variant

13 (8.1%)

N.A.

13 (16.7%)

N.A.

    Infected with Omicron

163 (12.3%)

N.A.

N.A.

163 (100%)

    Infection-naive

492 (37.1%)

492 (51.5%)

N.A.

N.A.

    Infection-naive but will be infected with Omicron

463 (34.9%)

463 (48.5%)

N.A.

N.A.

Time between first and second dose (days)

    Median (IQR)

30 (29–33)

30 (29–33)

30 (29–33)

30 (29–33)

0.7171e

Time between first and third dose (days)

    Median (IQR)

295 (287–302)

294 (287–302)

298 (291–309)

294 (285–302)

<0.0001e

  1. IQR Interquartile range, N.A. Not Applicable.
  2. aParticipants who contributed with a sample for the cellular immunity studies: 874 individuals.
  3. bParticipants who contributed with a sample for the cellular immunity studies: 651 individuals.
  4. cParticipants who contributed with a sample for the cellular immunity studies: 124 individuals.
  5. dParticipants who contributed with a sample for the cellular immunity studies: 99 individuals.
  6. eKruskal–Wallis test (two-sided) between participants infected before Omicron, participants infected with Omicron and infection-naive participants.
  7. fChi-squared test (two-sided) between participants infected before Omicron, participants infected with Omicron and infection-naive participants.
  8. gMissing values: 148 individuals.
  9. hMissing values: 102 individuals.
  10. iMissing values: 16 individuals.
  11. jMissing values: 30 individuals.
  12. kAncestral variant dominance in Denmark comprised a wide combination of the clades 20E (EU1), 20A (EU2), 20A/S:439K, 20B/S:626S, among others70.
Back to article page